行业回顾本报告期医药生物行业指数跌幅为1.07%，在申万31 个一级行业中位居第26，跑赢沪深300 指数（-1.19%）。从子行业来看，线下药店、医院涨幅居前，涨幅分别为10.25%、2.92%；化学制剂、疫苗跌幅居前，跌幅分别为4.50%、2.96%。估值方面，截至2026 年1 月23 日，医药生物行业PE（TTM 整体法，剔除负值）为30.31x（上期末30.56x），估值下行，低于均值。...
Source Link行业回顾本报告期医药生物行业指数跌幅为1.07%，在申万31 个一级行业中位居第26，跑赢沪深300 指数（-1.19%）。从子行业来看，线下药店、医院涨幅居前，涨幅分别为10.25%、2.92%；化学制剂、疫苗跌幅居前，跌幅分别为4.50%、2.96%。估值方面，截至2026 年1 月23 日，医药生物行业PE（TTM 整体法，剔除负值）为30.31x（上期末30.56x），估值下行，低于均值。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.